Improving Outcomes in Bladder Cancer

A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

Treatment with immune checkpoint inhibitors has improved survival outcomes for patients with metastatic bladder cancer, compared with chemotherapy.